Butterwick Kimberly, Lowe Nicholas J
Dermatology/Cosmetic Laser Associates of La Jolla Inc, La Jolla, California 92037, USA.
J Am Acad Dermatol. 2009 Aug;61(2):281-93. doi: 10.1016/j.jaad.2008.11.881.
Currently a diverse range of injectable agents are used for noninvasive facial enhancement. Injectable poly-L-lactic acid (PLLA) is a biocompatible, biodegradable, synthetic polymer that is approved for correction of HIV-related facial lipoatrophy in Europe, Canada, and the United States. PLLA is also approved in several countries for cosmetic purposes, and is under review in the United States for this indication. After injection, PLLA elicits a gradual increase in facial volume via hypothesized endogenous production of fibroblasts and, subsequently, collagen, enabling global facial rejuvenation to be tailored, as required, over time. Substantial increases in dermal thickness after injection of PLLA have been observed to last for up to 2 years. This article reviews the use of PLLA in Europe and the United States with regard to practitioner experiences and techniques for optimizing outcomes. Correct reconstitution and administration of PLLA have been found to be important parameters for optimal use of this agent.
目前，多种可注射制剂被用于非侵入性面部美容。可注射聚左旋乳酸（PLLA）是一种生物相容性、可生物降解的合成聚合物，在欧洲、加拿大和美国被批准用于治疗与人类免疫缺陷病毒（HIV）相关的面部脂肪萎缩。PLLA在多个国家也被批准用于美容目的，在美国正针对这一适应症进行审查。注射后，PLLA通过推测的内源性成纤维细胞生成以及随后的胶原蛋白生成，使面部容积逐渐增加，从而能够根据需要随着时间的推移进行全面的面部年轻化调整。注射PLLA后，真皮厚度显著增加已被观察到可持续长达2年。本文就欧洲和美国使用PLLA的情况，结合从业者的经验以及优化治疗效果的技术进行综述。已发现正确复溶和使用PLLA是最佳使用该制剂的重要参数。
